Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04926233 · ClinicalTrials.gov registry record
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,371,146
- Enrollment target
NCT04926233: Completed study, sponsored by Boehringer Ingelheim.
NCT04926233 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,371,146 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04926233 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,371,146 participants
- Enrollment target
Study Summary
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
Primary Outcome
Age of the chronic obstructive pulmonary disease (COPD) patients at the time of COPD diagnosis from the United States (US) IBM MarketScan was reported by groups stratified according to their COPD diagnosis times (Before versus after the approval of Tiotropium + Olodaterol in 2015).
Interventions
- DRUG Tiotropium bromide + Olodaterol
- DEVICE Sp(t)iolto® Respimat®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,371,146 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2020-04-14 |
What the finished NCT04926233 record still lists
NCT04926233 is an observational study that tracks outcomes without assigning an intervention. Its 1,371,146 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium bromide + Olodaterol is the first listed.
NCT04926233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04926233 about?
NCT04926233 is a clinical study titled "Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study". The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
What is the current status of trial NCT04926233?
This trial is currently completed. The enrollment target is 1,371,146 participants. The study started on 2019-11-15. Estimated completion is 2020-04-14.
What interventions are being tested in trial NCT04926233?
The interventions under investigation include: Tiotropium bromide + Olodaterol (DRUG), Sp(t)iolto® Respimat® (DEVICE).
Who is sponsoring clinical trial NCT04926233?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07022951 · 1,200,000 participants
The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
- NCT07224685 · 1,000,000 participants
A Study of Mayo Clinic CV Research Heart & Voice Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI